Yuli Wu, MD, has over 20 years of experience in pharmaceutical and biotech companies, with extensive experience in global drug safety and pharmacovigilance across various therapeutic areas including neuroscience. Yuli joined Acumen as VP, Drug safety & Pharmacovigilance in 2023. Prior to joining Acumen, Yuli served as the head of Drug Safety & Pharmacovigilance US/EU at Zai Lab, overseeing clinical trial safety, signal detection, safety evaluation and risk management, as well as safety-related regulatory interactions for the company’s products throughout their life cycle. Previously, Yuli served as the head of Safety Evaluation & Risk Management at Tesaro/GSK, where she contributed to the successful development and commercialization of Zejula® (niraparib) and Jemperli® (dostarlimab). Yuli received her MD from Peking Union Medical College in Beijing, China. She completed her postdoctoral training at Jefferson Institute of Molecular Medicine and fellowship at Fox Chase Cancer Center in Philadelphia.